ArticleEuropean journal of nuclear medicine and molecular imaging2019
Regional changes in the type 1 cannabinoid receptor are associated with cognitive dysfunction in Parkinson's disease.
Article in European journal of nuclear medicine and molecular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 28 citations in OpenAlex.
- Deficits in episodic memory and executive functions in relation to CB1 receptor availability in Parkinson's disease.Journal of Parkinson's disease · 2026Article
- Cannabidiol prevents cognitive and social deficits in a male rat model of Alzheimer's disease through CB1 activation and inflammation modulation.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Article
- Cannabinoid Receptor 1: The Neural Gatekeeper of Health and Disease.Current neurovascular research · 2025Review
- The endocannabinoid system in the brain undergoes long-lasting changes following neuropathic pain.iScience · 2024Review
- Therapeutic Application of Modulators of Endogenous Cannabinoid System in Parkinson's Disease.International journal of molecular sciences · 2024Review
- Laminar Distribution of Cannabinoid Receptor 1 in the Prefrontal Cortex of Nonhuman Primates.Molecular neurobiology · 2024Article
- Resting State Brain Networks under Inverse Agonist versus Complete Knockout of the Cannabinoid Receptor 1.ACS chemical neuroscience · 2024Article
- Neuroinflammation and Mitochondrial Dysfunction in Parkinson's Disease: Connecting Neuroimaging with Pathophysiology.Antioxidants (Basel, Switzerland) · 2023Review
- Altered Neurovascular Coupling for Multidisciplinary Intensive Rehabilitation in Parkinson's Disease.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2023Article
- Negative relationship between brain-derived neurotrophic factor (BDNF) and attention: A possible elevation in BDNF level among high-altitude migrants.Frontiers in neurology · 2023Article
- Impact of the Cannabinoid System in Alzheimer's Disease.Current neuropharmacology · 2023Review
- Cannabinoid Receptor Type 1 in Parkinson's Disease: A Positron Emission Tomography Study with [Movement disorders : official journal of the Movement Disorder Society · 2022Article
- Time-Course of Alterations in the Endocannabinoid System after Viral-Mediated Overexpression of α-Synuclein in the Rat Brain.Molecules (Basel, Switzerland) · 2022Article
- Autoencoder Networks Decipher the Association between Lung Cancer and Alzheimer's Disease.Computational intelligence and neuroscience · 2022Article
- Identification of hub genes associated with cognition in the hippocampus of Alzheimer's Disease.Bioengineered · 2021Article
- Progress on the application of positron emission tomography imaging of cannabinoid type 1 receptor in neuropsychiatric diseases.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2021Review
- Positron Emission Tomography Imaging of the Endocannabinoid System: Opportunities and Challenges in Radiotracer Development.Journal of medicinal chemistry · 2021Review
- Can Physical Activity Support the Endocannabinoid System in the Preventive and Therapeutic Approach to Neurological Disorders?International journal of molecular sciences · 2020Review
- Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies.The EPMA journal · 2020Review
- Recovery of BDNF and CB1R in the Prefrontal Cortex Underlying Improvement of Working Memory in Prenatal DEHP-Exposed Male Rats after Aerobic Exercise.International journal of molecular sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe endocannabinoid system plays a regulatory role in a number of physiological functions, including motor control but also mood, emotion, and cognition. A number of preclinical studies in Parkinson's disease (PD) models demonstrated that modulating the type 1 cannabinoid receptor (CB
methodsThirty-eight PD patients and ten age- and gender-matched controls underwent a [
resultsPD patients with poorer performance in episodic memory, executive functioning, speed and mental flexibility (range P 0.003-0.03) showed lower CB
conclusionsDecreased CB
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.